Claudin 18.2 ADC LM-302 obtained FDA Orphan Drug Designation in May 2021 for indications of pancreatic, gastric, and gastroesophageal junction cancers.
Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.
